Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Hinokiflavone is a biflavonoid that has been found in A. dammara and has diverse biological activities.1,2,3,4 It inhibits the aggregation of amyloid-β (1-40) (Aβ40; Item No. 21617) in vitro (IC50 = 9.5 μM).1 Hinokiflavone (10 µM) promotes pre-mRNA splicing of the genes encoding myeloid cell leukemia-1 (Mcl-1) and eukaryotic translation initiation factor 4α subunit (eIF4α) and inhibits pre-mRNA splicing of the genes encoding heat shock protein 40 (Hsp40) and RIO kinase 3 (RIOK3) in NB4 cells, as well as increases protein SUMOylation in HEK293 cells.2 It has antiviral activity against the influenza A subtypes H1N1 and H1N3, influenza B, parainfluenza type 3, and respiratory syncytial virus (RSV) in cytopathic effect assays (IC50s = 1.4, 1.3, 1.2, 1, and 2.5 µg/ml, respectively).3 Hinokiflavone (10-40 µM) inhibits the migration and invasion of, and induces apoptosis in, KYSE-150 esophageal squamous cell carcinoma (ESCC) cells in vitro and reduces tumor volume in a KYSE-150 mouse xenograft model when administered at doses of 25 or 50 mg/kg.4
WARNING This product is not for human or veterinary use.
1. Naturally occurring biflavonoids with amyloid β aggregation inhibitory activity for development of anti-
2. Characterisation of the biflavonoid hinokiflavone as a pre-
3. Antiviral activities of biflavonoids. Planta. Med. 65(2), 120-125 (1999).
4. Hinokiflavone inhibits growth of esophageal squamous cancer by inducing apoptosis via regulation of the PI3K/AKT/mTOR signaling pathway. Front. Oncol. 12:833719, (2022).